^
Association details:
| Biomarker: | PIK3CA H1047R |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) + dactolisib (RTB101) (mTOR inhibitor, PI3K inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers
Excerpt:
Xenografts developed from a HNSCC cell line harboring a PIK3CA mutation (H1047R) were more sensitive to the combination of BEZ-235 plus cetuximab (the only FDA-approved molecular targeting agent in HNSCC) compared with cetuximab alone (Supplemental Figure 4), suggesting that targeting PI3K in the setting of PIK3CA mutant tumors can enhance treatment responses to cetuximab.
DOI:
10.1158/2159-8290.CD-13-0103
